P Nijeboer1, Rlj van Wanrooij1, T van Gils1, N J Wierdsma2, G J Tack1, B I Witte3, H J Bontkes4, O Visser5, Cjj Mulder1, G Bouma1. 1. Department of Gastroenterology, VU University Medical Centre, Amsterdam, The Netherlands. 2. Department of Nutrition and Dietetics, VU University Medical Centre, Amsterdam, The Netherlands. 3. Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands. 4. Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands. 5. Department of Haematology, VU University Medical Centre, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Refractory coeliac disease type II (RCDII) frequently transforms into an enteropathy-associated T-cell lymphoma (EATL) and therefore requires intensive treatment. Current evaluated treatment strategies for RCDII include cladribine (2-CdA) and autologous stem cell transplantation (auSCT). OBJECTIVE: The purpose of this study was to evaluate long-term survival and define clear prognostic criteria for EATL development comparing two treatment strategies. METHODS: A total of 45 patients were retrospectively analysed. All patients received 2-CdA, after which they were either closely monitored (monotherapy, n = 30) or a step-up approach was used including auSCT (step-up therapy, n = 15). RESULTS: Ten patients (22%) ultimately developed EATL; nine of these had received monotherapy. Absence of histological remission after monotherapy was associated with EATL development (p = 0.010). Overall, 20 patients (44%) died with a median survival of 84 months. Overall survival (OS) within the monotherapy group was significantly worse in those without histological remission compared to those with complete histological remission(p = 0.030). The monotherapy group who achieved complete histological remission showed comparable EATL occurrence and OS as compared to the step-up therapy group (p = 0.80 and p = 0.14 respectively). CONCLUSION: Histological response is an accurate parameter to evaluate the effect of 2-CdA therapy and this parameter should be leading in the decisions whether or not to perform a step-up treatment approach in RCDII.
BACKGROUND: Refractory coeliac disease type II (RCDII) frequently transforms into an enteropathy-associated T-cell lymphoma (EATL) and therefore requires intensive treatment. Current evaluated treatment strategies for RCDII include cladribine (2-CdA) and autologous stem cell transplantation (auSCT). OBJECTIVE: The purpose of this study was to evaluate long-term survival and define clear prognostic criteria for EATL development comparing two treatment strategies. METHODS: A total of 45 patients were retrospectively analysed. All patients received 2-CdA, after which they were either closely monitored (monotherapy, n = 30) or a step-up approach was used including auSCT (step-up therapy, n = 15). RESULTS: Ten patients (22%) ultimately developed EATL; nine of these had received monotherapy. Absence of histological remission after monotherapy was associated with EATL development (p = 0.010). Overall, 20 patients (44%) died with a median survival of 84 months. Overall survival (OS) within the monotherapy group was significantly worse in those without histological remission compared to those with complete histological remission(p = 0.030). The monotherapy group who achieved complete histological remission showed comparable EATL occurrence and OS as compared to the step-up therapy group (p = 0.80 and p = 0.14 respectively). CONCLUSION: Histological response is an accurate parameter to evaluate the effect of 2-CdA therapy and this parameter should be leading in the decisions whether or not to perform a step-up treatment approach in RCDII.
Authors: Greetje J Tack; Wieke H M Verbeek; Abdul Al-Toma; Dirk J Kuik; Marco W J Schreurs; Otto Visser; Chris J J Mulder Journal: World J Gastroenterol Date: 2011-01-28 Impact factor: 5.742
Authors: Wieke H M Verbeek; Marco W J Schreurs; Otto J Visser; B Mary E von Blomberg; Abdulbaqi Al-Toma; Chris J J Mulder Journal: Expert Rev Clin Immunol Date: 2008-03 Impact factor: 4.473
Authors: Stijn J B Van Weyenberg; Sietze T Van Turenhout; Gerd Bouma; Jan Hein T M Van Waesberghe; Donald L Van der Peet; Chris J J Mulder; Maarten A J M Jacobs Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Stijn J B Van Weyenberg; Martijn R Meijerink; Maarten A J M Jacobs; Cornelis van Kuijk; Chris J Mulder; Jan Hein T M van Waesberghe Journal: Radiology Date: 2011-02-17 Impact factor: 11.105
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Wieke H M Verbeek; Marije S Goerres; B Mary E von Blomberg; Joost J Oudejans; Petra E T Scholten; Muhammed Hadithi; Abdul Al-Toma; Marco W J Schreurs; Chris J J Mulder Journal: Clin Immunol Date: 2007-11-26 Impact factor: 3.969
Authors: Abdulbaqi Al-Toma; Marije S Goerres; Jos W R Meijer; A Salvador Peña; J Bart A Crusius; Chris J J Mulder Journal: Clin Gastroenterol Hepatol Date: 2006-03 Impact factor: 11.382